|
Daily Medical Update
Infections of the pleural space and empyema
Friday, August 07, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
European Respiratory Review (2026) - Systematic Review and Meta-Analysis
Key Findings
- Pooled hospital length of stay was 12.9 days with intrapleural enzyme therapy versus 22.7 days with standard care.
- Surgery was required in 11.5% of the intrapleural enzyme therapy group versus 23.4% with standard care.
- In-hospital mortality was 3.7% with intrapleural enzyme therapy versus 13.7% with standard care, while significant bleeding occurred in 3.7%.
📋 Practice Implication: For appropriately selected pleural infection, early tPA/DNase is a reasonable strategy to reduce treatment duration and the likelihood of surgery while maintaining a relatively low major-bleeding rate.
|
Italian Journal of Pediatrics (2025) - Randomized Controlled Trial
Key Findings
- Median hospital stay was 9.5 days with intrapleural dexamethasone versus 16 days in the control group.
- Median fever duration was 5 days with dexamethasone versus 11 days without it, and median CRP was 12.5 versus 21.
- There was no significant improvement in oxygen saturation or reduction in chest-tube duration between groups.
📋 Practice Implication: Adjunctive intrapleural dexamethasone may accelerate inflammatory and clinical recovery in children receiving antibiotics plus fibrinolysis, but the unchanged drainage-related outcomes argue against viewing it as a substitute for source control.
|
Indian Journal of Pediatrics (2025) - Randomized Controlled Trial
Key Findings
- Six streptokinase doses produced greater cumulative pleural pus drainage than three doses: 367 versus 195 mL.
- After therapy, fever lasted 2.3 days with six doses versus 5.7 days with three, and respiratory distress lasted 2.2 versus 6.3 days.
- Six doses did not significantly reduce hospital stay or drainage duration, or increase treatment failure, decortication, adverse effects, or cost.
📋 Practice Implication: A six-dose pediatric streptokinase schedule may improve drainage and symptom resolution without increasing observed toxicity, although it did not clearly reduce hospitalization or surgery in this small trial.
|
Pediatric Pulmonology (2025) - Systematic Review and Meta-Analysis
Key Findings
- Conservative treatment increased hospital stay by 1.82 days compared with surgery.
- Treatment failure was higher with conservative management than with surgery (RR 2.03, 95% CI 1.22-3.40).
- Complication rates did not differ significantly (RR 0.92, 95% CI 0.54-1.56), and overall mortality was low.
📋 Practice Implication: In children with complicated community-acquired pneumonia, persistent or severe disease should prompt timely surgical evaluation, while heterogeneity means the review does not establish a universal threshold for early surgery.
|
Journal of Bronchology & Interventional Pulmonology (2025) - Multicenter Observational Study
Key Findings
- Among 185 patients treated with intrapleural enzyme therapy, 57 (30.8%) experienced treatment failure requiring escalation or surgery.
- A community source of infection predicted treatment success, whereas a hospital source was associated with lower odds of success (OR 0.287, 95% CI 0.115-0.690).
- Clinical and radiologic improvement without surgery was achieved in the remaining 128 patients after 57 treatment failures.
📋 Practice Implication: Use infection setting as an early risk signal when planning tPA/DNase treatment, with hospital-acquired disease warranting closer reassessment and earlier surgical involvement if response is inadequate.
|
|
💡
Summary
Across the highest-significance studies, intrapleural enzyme therapy was associated with shorter hospitalization, fewer operations, and lower in-hospital mortality than standard care, while six-dose streptokinase and adjunctive dexamethasone improved selected pediatric recovery outcomes. Pediatric meta-analysis favored surgery over conservative treatment for length of stay and treatment failure, but substantial heterogeneity and the observational nature of treatment-predictor data support individualized escalation decisions.
|
|